Last reviewed · How we verify
Adalat (Nifedipine, BAYA1040)
Nifedipine blocks calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and reduced blood pressure.
Nifedipine blocks calcium influx into vascular smooth muscle and cardiac cells, causing vasodilation and reduced blood pressure. Used for Hypertension, Angina pectoris (chronic stable angina), Vasospastic angina (Prinzmetal's angina).
At a glance
| Generic name | Adalat (Nifedipine, BAYA1040) |
|---|---|
| Sponsor | Bayer |
| Drug class | Calcium channel blocker (dihydropyridine) |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nifedipine is a dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in the cell membrane. By preventing calcium entry into vascular smooth muscle cells, it reduces intracellular calcium concentration, leading to relaxation of vascular smooth muscle and coronary vasodilation. This results in decreased peripheral vascular resistance and improved coronary blood flow.
Approved indications
- Hypertension
- Angina pectoris (chronic stable angina)
- Vasospastic angina (Prinzmetal's angina)
Common side effects
- Headache
- Flushing
- Dizziness
- Peripheral edema
- Palpitations
- Fatigue
- Nausea
Key clinical trials
- Postpartum Preeclampsia Early Detection and Treatment: Nepal Pilot Study (NA)
- PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA. (PHASE3)
- 6-year Outcomes in Children After Nifedipine vs Placebo for Preterm Prelabor Rupture of Membranes at 22-33 Weeks
- Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- Safest Choice of Antihypertensive Regimen for Postpartum Hypertension (PHASE3)
- Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study (NA)
- Topical Nifedipine 0.3% Plus Lidocaine 1.5% for Uncomplicated Hemorrhoidal Disease
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Adalat (Nifedipine, BAYA1040) CI brief — competitive landscape report
- Adalat (Nifedipine, BAYA1040) updates RSS · CI watch RSS
- Bayer portfolio CI